INFANTS Act of 2025
- Sponsor
- Rep. Sykes, Emilia Strong [D-OH-13]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Mar 27, 2025
Bottom line
This bill establishes mandatory contaminant testing for infant and toddler foods, grants the FDA expanded recall powers, and enhances pathogen monitoring and reporting for infant formula to improve child food safety.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to mandate quarterly testing for toxic contaminants like lead, cadmium, mercury, and arsenic in infant and toddler foods. It expands the FDA's authority to include mandatory recalls for adulterated infant and toddler foods and strengthens reporting and environmental monitoring requirements for infant formula manufacturers regarding pathogen contamination. Failure to comply with the new testing requirements would render the food adulterated.
Proponents argue
Proponents argue this bill is essential for protecting the health of infants and toddlers, who are particularly vulnerable to the developmental harms caused by exposure to toxic heavy metals and pathogens in food. They contend that current regulations are insufficient and that mandatory testing, enhanced reporting, and recall authority will increase consumer confidence and prevent future public health crises related to contaminated baby food and infant formula.
Opponents contend
Opponents, primarily from the food manufacturing industry, may argue that the bill imposes significant new compliance costs that could lead to higher product prices or reduced availability, particularly for smaller businesses. They might also contend that existing voluntary industry standards and general food safety regulations are adequate, and that some provisions, such as strict 24-hour reporting, could lead to unnecessary alarms or operational disruptions.
The bill is relatively short and clearly structured, making it accessible for a thorough review within a reasonable timeframe.
Section 2
Definition of Infant and Toddler Food
This section adds a new definition to the Federal Food, Drug, and Cosmetic Act, specifying that 'infant and toddler food' refers to any food represented as suitable for children up to 24 months of age, explicitly including infant formula. This definition establishes the scope for all subsequent regulatory requirements introduced by the bill.
Supporters argue
Proponents argue that a clear and explicit definition is foundational for effective regulation, ensuring that all products intended for this vulnerable age group are subject to the same rigorous safety standards.
Critics contend
No specific opposition is typically raised against the definition itself, though it forms the basis for regulations that manufacturers may oppose.
Tradeoffs
The provision aims to provide regulatory clarity, which is generally uncontroversial, but its breadth sets the stage for potentially extensive new compliance obligations.
Section 3 (adding Section 425 to FD&C Act)
Mandatory Quarterly Testing for Contaminants in Infant and Toddler Food
This provision requires facilities manufacturing infant and toddler food to collect representative samples of each food product and conduct quarterly testing for specified contaminants, including lead, cadmium, mercury, and arsenic. Manufacturers must develop a written sampling plan, use accredited laboratories for testing, and maintain detailed records of all testing for at least two years or the product's shelf-life. These records must be made available to the FDA upon request.
Section 4 (amending Section 402 of FD&C Act)
Failure to Comply with Testing Requirements Constitutes Adulteration
This section amends the Federal Food, Drug, and Cosmetic Act to specify that an article of food (specifically infant and toddler food) is considered 'adulterated' if the manufacturing facility fails to comply with the new sampling and testing requirements outlined in Section 425. This provides a direct legal pathway for the FDA to take enforcement actions against non-compliant manufacturers, even if the food's contaminant levels are not yet definitively proven to be harmful.
Section 6 (amending Section 423(a) of FD&C Act)
Mandatory Recall Authority for Adulterated Infant and Toddler Food
This section grants the Secretary of Health and Human Services (acting through the FDA) the authority to mandate a recall of infant and toddler food (excluding infant formula, which already has this authority) if it is determined that the product contains a contaminant that renders it adulterated under Section 402(a)(1). This significantly expands the FDA's power to remove unsafe products from the market quickly.
Section 7 (amending Section 412(e) of FD&C Act)
Enhanced Reporting for Infant Formula Pathogen Contamination
This section requires infant formula manufacturers to notify the Secretary within 24 hours of confirming a positive analytical result for any environmental pathogen in in-process or finished product testing. Manufacturers must also consult with the Secretary for proper disposal of affected product and provide results and isolates from positive samples. The FDA is then required to confirm that the manufacturer has performed appropriate corrective action within 90 days of notification.
Section 8 (adding Section 412(n) to FD&C Act)
Mandatory Environmental Monitoring for Powdered Infant Formula Facilities
This section mandates that manufacturers of powdered infant formula establish and implement an environmental monitoring program to verify the effectiveness of sanitation and hygiene controls against Cronobacter spp. and Salmonella. The program must be written, detailing sampling locations, number of samples, and frequency of collection and testing. Records of this monitoring must be maintained for at least two years or the product's shelf-life and made available to the FDA upon request.
This section expands the FDA's authority to request records and information from food establishments (including those manufacturing infant and toddler food) in advance of or in lieu of an inspection. These records can be requested within a reasonable timeframe, limits, and manner, in either electronic or physical form, at the expense of the facility. It also clarifies that Section 703 (public disclosure of records) does not apply to these requests.
Section 5 (amending Section 704(a)(4) of FD&C Act)
Why it matters:Amending existing statutes is standard legislative practice for integrating new powers or clarifying existing ones. The technical nature of statutory cross-references can make such changes less visible.
Case for: Proponents argue that this expanded authority streamlines FDA oversight, allowing for more efficient review of compliance and potential issues without always requiring an immediate on-site inspection. This can be particularly useful for remote monitoring and faster response times.
Case against: Industry groups may raise concerns about the burden of providing extensive records remotely, potential for overreach by the FDA, and the costs associated with fulfilling such requests. They might also express privacy concerns regarding the scope of information requested.
Estimated impact: This provision significantly enhances the FDA's ability to conduct off-site surveillance and compliance checks across the entire food industry, potentially increasing the frequency and depth of regulatory scrutiny without physical inspections.
Both the mandatory sampling and testing requirements for contaminants (Section 3) and the environmental monitoring requirements for powdered infant formula (Section 8) include 'Delayed Applicability' clauses. Section 3(e) states that its requirements apply 180 days after the Secretary publishes guidance required by the bill. Section 8(6) states its requirements apply 180 days after the date of enactment of that subsection.
Section 3(e) and Section 8(6)
Why it matters:Delayed applicability is standard legislative practice to provide agencies time to develop necessary guidance and for regulated entities to prepare for compliance. It is not necessarily evasive, but its placement can make it less prominent.
Case for: Proponents argue that these delays are practical and necessary to allow the FDA to issue clear guidance and for manufacturers to implement complex new systems (like sampling plans and environmental monitoring programs) without immediate disruption. This ensures a smoother transition to the new regulatory framework.
Case against: Critics might argue that such delays postpone critical safety improvements, especially given the urgency implied by the bill's focus on vulnerable populations. They might advocate for faster implementation where feasible.
Estimated impact: These clauses mean that the most significant new safety measures will not take effect immediately upon the bill's enactment, but rather after a period of several months, allowing for preparatory work by both regulators and industry.